Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CYP8B1 | Q9UNU6 | 3/20 | 0.39 |
| ▸ | IDE | P14735 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4582815 | 0.93 | MAPK1 (0.51) | PDGFRBMAPK1KDM4EMAPTMEN1 | |
| SCHEMBL4582933 | 0.86 | PDGFRB (0.47) | PDGFRBMAPK1KDM4EMAPTMEN1 | |
| SCHEMBL4583524 | 0.86 | PDGFRB (0.58) | PDGFRBKDM4EMAPTALDH1A1IDE | |
| SCHEMBL4585528 | 0.85 | PDGFRB (0.50) | PDGFRBKDM4EMAPTMEN1KMT2A | |
| SCHEMBL4584606 | 0.85 | PDGFRB (0.46) | PDGFRBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL4583179 | 0.84 | ALDH1A1 (0.40) | KDM4EMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL4582530 | 0.84 | KDM4E (0.47) | PDGFRBMAPK1KDM4EMAPTMEN1 | |
| SCHEMBL4583309 | 0.82 | HTT (0.51) | PDGFRBMAPK1KDM4EMAPTALDH1A1 | |
| SCHEMBL4583105 | 0.81 | CYP1A2 (0.48) | PDGFRBMAPTMEN1KMT2A | |
| SCHEMBL4583204 | 0.80 | PDGFRB (0.56) | PDGFRBKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | claimed |
| EP-1903037-A1 | 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
| EP-1903037-A1 | 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2008028690-A1 | 1-(HET)ARYL-3-[HETARYL-PIPERIDIN-4-YL]-THIOUREAS AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | PTGER2, PTGER1, PTGES2 | PDGFRB 129/4885MAPK1 2377/4885KDM4E 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.